EE200200530A - Glükogeenfosforülaasi inhibiitorite farmatseutilised kompositsioonid - Google Patents

Glükogeenfosforülaasi inhibiitorite farmatseutilised kompositsioonid

Info

Publication number
EE200200530A
EE200200530A EEP200200530A EEP200200530A EE200200530A EE 200200530 A EE200200530 A EE 200200530A EE P200200530 A EEP200200530 A EE P200200530A EE P200200530 A EEP200200530 A EE P200200530A EE 200200530 A EE200200530 A EE 200200530A
Authority
EE
Estonia
Prior art keywords
pharmaceutical compositions
glycogen phosphorylase
phosphorylase inhibitors
inhibitors
glycogen
Prior art date
Application number
EEP200200530A
Other languages
English (en)
Estonian (et)
Inventor
Jay Hoover Dennis
Mysore Shanker Ravi
Thomas Friesen Dwayne
Alan Lorenz Douglas
Alan Schriver Nightingale James
Original Assignee
Pfizer Products Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc. filed Critical Pfizer Products Inc.
Publication of EE200200530A publication Critical patent/EE200200530A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
EEP200200530A 2000-03-16 2001-03-16 Glükogeenfosforülaasi inhibiitorite farmatseutilised kompositsioonid EE200200530A (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18994200P 2000-03-16 2000-03-16
PCT/IB2001/000394 WO2001068055A1 (fr) 2000-03-16 2001-03-16 Compositions pharmaceutiques d'inhibiteurs du glycogene phosphorylase

Publications (1)

Publication Number Publication Date
EE200200530A true EE200200530A (et) 2004-04-15

Family

ID=22699402

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200200530A EE200200530A (et) 2000-03-16 2001-03-16 Glükogeenfosforülaasi inhibiitorite farmatseutilised kompositsioonid

Country Status (32)

Country Link
US (1) US20010053778A1 (fr)
EP (1) EP1263414A1 (fr)
JP (1) JP2003526654A (fr)
KR (1) KR20020081445A (fr)
CN (1) CN1418089A (fr)
AP (1) AP2002002621A0 (fr)
AR (1) AR027656A1 (fr)
AU (1) AU2001242669A1 (fr)
BG (1) BG107037A (fr)
BR (1) BR0109189A (fr)
CA (1) CA2403241A1 (fr)
CO (1) CO5280087A1 (fr)
CZ (1) CZ20022955A3 (fr)
EA (1) EA200200858A1 (fr)
EE (1) EE200200530A (fr)
HU (1) HUP0204583A2 (fr)
IL (1) IL151320A0 (fr)
IS (1) IS6508A (fr)
MA (1) MA26882A1 (fr)
MX (1) MXPA02009097A (fr)
NO (1) NO20024386L (fr)
OA (1) OA12232A (fr)
PA (1) PA8513601A1 (fr)
PE (1) PE20011184A1 (fr)
PL (1) PL360780A1 (fr)
SK (1) SK12622002A3 (fr)
SV (1) SV2002000343A (fr)
TN (1) TNSN01040A1 (fr)
TR (1) TR200202184T2 (fr)
WO (1) WO2001068055A1 (fr)
YU (1) YU67202A (fr)
ZA (1) ZA200207290B (fr)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1402629A (zh) * 1999-12-23 2003-03-12 辉瑞产品公司 提供提高的药物浓度的药物组合物
CO5271699A1 (es) 2000-01-24 2003-04-30 Pfizer Prod Inc Procedimiento para el tratamiento de cardiomiopatia utilizando inhibidores de la glucogeno fosforilasa
WO2002070478A1 (fr) 2001-03-06 2002-09-12 Astrazeneca Ab Dérivés indolone capable de dégrader des vaisseaux
JP2004534812A (ja) 2001-06-22 2004-11-18 ファイザー・プロダクツ・インク 薬物および中性ポリマーの分散物の医薬組成物
OA12625A (en) 2001-06-22 2006-06-12 Pfizer Prod Inc Pharmaceutical compositions of adsorbates of amorphous drug.
EP1269994A3 (fr) 2001-06-22 2003-02-12 Pfizer Products Inc. Compositions Pharmaceutiques comprenant un médicament et un polymère permettant d'améliorer la concentration du médicament
CA2450748A1 (fr) * 2001-06-22 2003-01-03 Pfizer Products Inc. Compositions pharmaceutiques contenant des ensembles polymere et medicament
DE60320940D1 (de) 2002-02-01 2008-06-26 Pfizer Prod Inc Pharmazeutische zusammensetzungen amorpher dispersionen von wirkstoffen und lipophiler mikrophasenbildender materialien
PL372247A1 (en) 2002-02-01 2005-07-11 Pfizer Products Inc. Method for making homogeneous spray-dried solid amorphous drug dispersions utilizing modified spray-drying apparatus
BR0307515A (pt) 2002-02-01 2004-12-07 Pfizer Prod Inc Método para fabricar dispersões de drogas amorfas sólidas secas por aspersão homogêneas usando bicos de pressão
GB0205170D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205175D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205176D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205162D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205166D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205165D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
US7405210B2 (en) 2003-05-21 2008-07-29 Osi Pharmaceuticals, Inc. Pyrrolopyridine-2-carboxylic acid amide inhibitors of glycogen phosphorylase
BRPI0413277A (pt) * 2003-08-04 2006-10-10 Pfizer Prod Inc composições farmacêuticas de adsorvatos de medicamentos amorfos e materiais que formam microfases lipofìlicas
CL2004001884A1 (es) 2003-08-04 2005-06-03 Pfizer Prod Inc Procedimiento de secado por pulverizacion para la formacion de dispersiones solidas amorfas de un farmaco y polimeros.
US7390503B1 (en) 2003-08-22 2008-06-24 Barr Laboratories, Inc. Ondansetron orally disintegrating tablets
JP2007517016A (ja) * 2003-12-31 2007-06-28 ファイザー・プロダクツ・インク 低溶解性薬剤及びポロキサマーの固体組成物
DE602005023965D1 (de) 2004-03-08 2010-11-18 Prosidion Ltd Pyrrolopyridin-2-carbonsäurehydrazide als inhibitoren von glykogenphosphorylase
US20090298745A1 (en) * 2004-12-02 2009-12-03 Gerard Hugh Thomas Treatment of Diabetes with Glycogen Phosphorylase Inhibitors
DE102005026755A1 (de) * 2005-06-09 2006-12-14 Basf Ag Herstellung von festen Lösungen schwerlöslicher Wirkstoffe durch Kurzzeitüberhitzung und schnelle Trocknung
MX374548B (es) 2012-08-24 2025-03-06 Dow Global Technologies Llc Eteres de celulosa esterificados novedosos de alto peso molecular y homogeneidad.
JP6404217B2 (ja) 2012-09-11 2018-10-10 メディベイション プロステイト セラピューティクス エルエルシー エンザルタミドの製剤
WO2015009566A1 (fr) * 2013-07-19 2015-01-22 Siga Technologies, Inc. Préparation de tecovirimat amorphe
CN103709171B (zh) * 2014-01-20 2015-09-16 武汉大学 具有哒嗪并[3,4-b]吲哚骨架结构的衍生物及其合成方法
ES3063790T3 (en) 2015-06-09 2026-04-20 Lonza Sales Ag Formulations to achieve rapid dissolution of drug from spray-dried dispersions in capsules
CN112442022B (zh) * 2019-09-02 2022-05-20 承德医学院 苯并嗪-4-酮类化合物、其制备方法及医药用途
US11291701B1 (en) * 2021-02-04 2022-04-05 Seed Edibles Orally disintegrating, sublingual and buccal formulations
US20250241586A1 (en) * 2024-01-04 2025-07-31 Debasish Banerjee Bioavailability and bioequivalence through intrinsic activity and KD measurements, in vivo, in humans

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI974437A7 (fi) * 1995-06-06 1997-12-05 Pfizer Substituoituja N-(indoli-2-karbonyyli)amideja ja johdannaisia glykogee nifosforylaasi-inhibiittoreina
DE69523182T2 (de) * 1995-06-06 2002-02-07 Pfizer Substituierte n-(indol-2-carbonyl)-glycinamide und derivate als glycogen phosphorylase inhibitoren
ES2287971T3 (es) * 1997-08-11 2007-12-16 Pfizer Products Inc. Dispersiones farmaceuticas solidas con biodisponibilidad incrementada.
US5998463A (en) * 1998-02-27 1999-12-07 Pfizer Inc Glycogen phosphorylase inhibitors

Also Published As

Publication number Publication date
BG107037A (bg) 2003-04-30
US20010053778A1 (en) 2001-12-20
IS6508A (is) 2002-08-16
CA2403241A1 (fr) 2001-09-20
HUP0204583A2 (hu) 2003-04-28
EA200200858A1 (ru) 2003-02-27
PE20011184A1 (es) 2001-11-15
PA8513601A1 (es) 2004-08-31
YU67202A (sh) 2006-01-16
TR200202184T2 (tr) 2003-01-21
PL360780A1 (en) 2004-09-20
CN1418089A (zh) 2003-05-14
NO20024386L (no) 2002-11-13
AU2001242669A1 (en) 2001-09-24
CZ20022955A3 (cs) 2003-09-17
MXPA02009097A (es) 2003-03-12
AP2002002621A0 (en) 2002-09-30
AR027656A1 (es) 2003-04-09
WO2001068055A1 (fr) 2001-09-20
SK12622002A3 (sk) 2004-02-03
EP1263414A1 (fr) 2002-12-11
OA12232A (en) 2006-05-10
TNSN01040A1 (fr) 2005-11-10
JP2003526654A (ja) 2003-09-09
NO20024386D0 (no) 2002-09-13
IL151320A0 (en) 2003-04-10
KR20020081445A (ko) 2002-10-26
CO5280087A1 (es) 2003-05-30
SV2002000343A (es) 2002-07-03
MA26882A1 (fr) 2004-12-20
ZA200207290B (en) 2003-09-11
BR0109189A (pt) 2003-05-27

Similar Documents

Publication Publication Date Title
EE200200530A (et) Glükogeenfosforülaasi inhibiitorite farmatseutilised kompositsioonid
FI20105657L (fi) Farmaseuttisia koostumuksia
IL142113A0 (en) Use of glycogen phosphorylase inhibitors
ITMI20010748A0 (it) Composizioni farmaceutiche
HUP0302412A3 (en) Betha-carboline derivatives useful as inhibitors of phosphodiesterase and pharmaceutical compositions containing the same
HUP0303146A3 (en) 3-(4-amidopyrrol-2-ylmethlidene)-2-indolinone derivatives as protein kinase inhibitors and pharmaceutical compositions containing them
PT1250343E (pt) Composicoes de antibioticos de azalida
EE200300052A (et) Kolesterüülestri ülekandevalgu inhibiitorite farmatseutilised kompositsioonid
EE05020B1 (et) Glburiidi ravimkoostis
PT1585548T (pt) Composições e métodos de administração de agentes farmacológicos
FI20011478L (fi) Farmaseuttinen koostumus
NO20024175L (no) Azetidinderivater, deres fremstilling og farmasöytiske preparater inneholdende forbindelsene
DK1524266T3 (da) Farmaceutisk sammensætning
NO20024528L (no) Proteaseinhibitor, farmasoytisk sammensetning og anvendelse av forbindelsen
DK1458377T3 (da) Farmaceutiske sammensætninger indeholdende tegaserod
IS7051A (is) Lyfjasamsetningar
NO20026123L (no) Farmasöytiske sammensetninger
FI20022128L (fi) Farmaseuttinen koostumus
NO20031095L (no) Farmasoytiske sammensetninger
EE200300468A (et) Pravastatiini stabiilne farmatseutiline kompositsioon
ITMI20000554A0 (it) Derivati di n-desacetiltiocolchicina e composizioni farmaceutiche cheli contengono
IS6734A (is) Tríasólafleiður og lyfjasamsetningar sem innihalda þær
EE200300465A (et) Püridoindolooni derivaatidel põhinevad farmatseutilised kompositsioonid
NO20042074L (no) Makrolider inneholdende farmasoytiske sammensetninger
EE200200689A (et) Ravimkoostised